Search Results

Defence Therapeutics Expands Radiopharmaceutical R&D Program to Evaluate Alpha and Beta Emitter Applications

MONTREAL, Quebec, Canada — Biotechnology company Defence Therapeutics Inc. recently announced the expansion of its radiopharmaceutical R&D program to include α and β radioisotopes in its evaluation scope, further validating the application potential of its proprietary Accum® technology in precision oncology. Defence Therapeutics is a publicly traded biotechnology company developing next-generation oncology treatments centered on its Accum® precision drug delivery platform. The company stated that the Accum® technology is designed to facilitate the entry of drug payloads into the intracellular compartment, thereby improving delivery efficiency. This expansion of the radiopharmaceutical program...

2026-09-01

Finland's 2025 Environmental Radiation Monitoring Shows No Harmful Effects from Nuclear Power Plant Operations

The 2025 environmental radiation monitoring results released recently by the Radiation and Nuclear Safety Authority of Finland (STUK) show that radioactive substance levels in the Finnish environment generally remained low, and the operation of the Loviisa and Olkiluoto nuclear power plants has not caused harmful radiation impacts on the public or the environment. STUK continuously tracks Finland's radiation situation through its environmental radiation monitoring program. The monitoring includes continuous measurement of external radiation, as well as monitoring of radioactive substances in air, radioactive fallout, water bodies, food, and the human body, with the aim of promptly detecting changes in radiation levels and confirming the safety of the living environment. Finland's automatic external radiation monitoring network covers essentially the entire country. In 2025, 255 monitoring...

2026-08-31

CNNC Changchun Nuclear Medicine Base Obtains Production License

On August 28, the Jilin Provincial Drug Administration approved and issued the "Radiopharmaceutical Production License" to Changchun Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as "Changchun Hi-Tech"), a subsidiary of Atomic Hi-Tech under China Isotope & Radiation Corporation (CIRC). The acquisition of this license marks that Changchun Hi-Tech is now fully qualified for the production of technetium-labeled drugs. Radiopharmaceuticals are characterized by short half-lives, high transportation requirements, and strict time sensitivity. Long-distance transportation not only increases transportation and time costs but also poses greater challenges to the stability and timeliness of clinical medication. With the production qualification, Changchun Hi-Tech will be able to complete the production and distribution of technetium-labeled drugs locally in Jilin Province, which will help improve the clinical use of nuclear medicine in the Northeast region...

2026-08-29

Russian Thorium-Based Radiopharmaceuticals Expected Within 1-2 Years

On August 27, Igor Korobko, Professor of the Russian Academy of Sciences and Director of the Department of Medical and Scientific Development in Healthcare of the Russian Ministry of Health, stated at the Technoprom Forum held in Novosibirsk that thorium-based drugs for precision radionuclide therapy of tumors are expected to become available in Russia within the next 1 to 2 years. Korobko noted that tumor treatment still requires support from more available isotopes. For example, when patients develop resistance to actinium-related therapies, clinical practice necessitates the use of different isotopes for treatment. He stated that Russia is advancing the development of related therapies domestically and expects to have thorium-based drugs within the next year or two. Currently, actinium-225 is considered one of the more promising radionuclides...

2026-08-28

Russia Advances Radiopharmaceutical Development, Plans to Expand into Diagnostics and Treatment of Heart Disease and Other Conditions

Rosatom is developing radiopharmaceuticals for the diagnosis and treatment of neurodegenerative diseases, heart disease, and rheumatic conditions, further expanding the application of radionuclide technology in medicine. During the 13th International Technology Development Forum Technoprom-2026 held in Novosibirsk, Sergei Surov, Director of the Department of Radionuclide Products and Nuclear Medicine at Rosatom's Science Division, stated that the company is advancing the development of these drugs. Radiopharmaceuticals typically contain radioactive isotopes, i.e., radionuclides, and are currently used in medicine primarily for the diagnosis and treatment of various cancers. Surov noted that the new development directions mean...

2026-08-28

Russia and Egypt Plan to Cooperate on Construction of Nuclear Medicine Center and Radiopharmaceutical Plant

Alexey Likhachev, CEO of Rosatom, recently stated that Russia and Egypt are expanding cooperation in non-energy nuclear technologies, with one of Egypt's key priorities being the construction of a high-performance nuclear medicine center based on a research reactor. According to reports, the project will adopt a comprehensive approach, including a radiopharmaceutical production plant, isotope production facilities, and modern diagnostic systems based on PET and SPECT technologies. Some diagnostic systems will use Russian equipment. Once completed, the project is expected to conduct up to 30,000 diagnostic examinations annually and provide treatment services for 400 patients. Construction of the medical facility is expected to begin as early as 2027...

2026-08-28

Bristol Myers Squibb to Invest $173 Million in New Radiopharmaceutical Plant in Indiana, USA

Bristol Myers Squibb's RayzeBio will build a new radiopharmaceutical production facility in Whitestown, Indiana, USA, with an investment of $173 million. The project will be located at the Anson Industrial Park in Boone County, with construction planned to begin this year, complementing RayzeBio's existing operational radiopharmaceutical plant in Indianapolis. According to information released by the state of Indiana, the new facility will cover approximately 225,000 square feet. Bristol Myers Squibb expects the two production sites to add 100 new positions by the end of 2029, with annual salaries for new positions expected to exceed $130,000. Bristol Myers Squibb acquired San Diego-based RayzeBio in 2023 for $4.1 billion...

2026-08-28

South Korea's Daewoong Pharmaceutical Partners with Promedius to Promote AI Osteoporosis Screening Solution Using Chest X-rays

Daewoong Pharmaceutical announced on August 27 that it has signed a sales, distribution, and joint promotion agreement with Promedius, a medical imaging AI company, to promote Osteo Signal, an AI-based osteoporosis risk screening solution using chest X-rays, in South Korea. This partnership also marks Daewoong Pharmaceutical's expansion from its existing osteoporosis treatment business into the AI-assisted diagnostics field. Under the agreement, Daewoong Pharmaceutical will leverage its business network covering medical institutions across South Korea, along with its sales and marketing capabilities, to bring the solution into more clinical settings. Promedius will provide medical imaging AI technical support to assist in its deployment in real-world medical environments.

2026-08-27

Moffitt Cancer Center in the U.S. Launches $600 Million Radiopharmaceutical Program

Moffitt Cancer Center in Tampa, Florida, recently announced the launch of a new radiopharmaceutical program, planning to accelerate radiopharmaceutical research, development, and clinical translation through a total infrastructure investment of $600 million. The program will be advanced at the Speros campus of Moffitt Cancer Center in Pasco County, Florida. The campus spans 775 acres, and the related investment will support the development of radiopharmaceutical research and development capabilities, including the construction of new radiochemistry laboratories within the Moffitt Discovery and Innovation Center, which opens this fall. The innovation center has a building area of approximately 255,000 square feet. The program funding will also support the planned comprehensive theranostics center...

2026-08-27

TEPCO replaces faulty motor of robotic arm at Fukushima Daiichi Unit 2

Tokyo Electric Power Company (TEPCO) began replacing the faulty motor of the robotic arm used for fuel debris retrieval trials at Unit 2 of the Fukushima Daiichi Nuclear Power Station on August 26. The robotic arm, approximately 22 meters long, is planned for use in the third fuel debris retrieval trial. During a previous operational inspection inside the reactor building of Unit 2, TEPCO found that the motor driving the robotic arm had malfunctioned, preventing the brake from releasing and the arm from extending. As the robotic arm is already installed on site, workers will enter the "front chamber" in front of the containment vessel to perform the replacement manually. The company stated that radiation levels in the work area will be strictly controlled to prevent workers from receiving excessive exposure. After this replacement, TEPCO will...

2026-08-27

U.S. Army Plans to Deploy Over 20 Micro Nuclear Reactors at Military Bases

The U.S. Army has signed contracts with five companies to develop, build, and operate micro nuclear power plants at military bases, with a total contract value of up to $2.2 billion. According to relevant information, the U.S. Department of Defense requires the companies to construct, own, and operate more than 20 micro nuclear reactors at military installations by 2028. The plan is intended to enhance energy security for critical defense facilities and reduce dependence on the external power grid. The deployment is incorporated into the framework of the Janus Project, which the U.S. Army launched in 2025. The project aims to establish a power supply network composed of compact micro nuclear reactors at military bases, providing continuous and stable electricity to vital defense facilities....

2026-08-27

Two production lines at radiopharmaceutical plant in Russia's Kaluga Region enter trial production

Rosatom recently announced that two production lines at its modern radiopharmaceutical manufacturing facility in the Kaluga Region have entered trial production. The facility, built in accordance with the Eurasian Economic Union's international Good Manufacturing Practice (GMP) standards, is equipped with high-level production equipment and is designed to supply safe, quality-controlled radiopharmaceuticals to the market. According to reports, Rosatom's subsidiary enterprises currently produce more than ten registered diagnostic and therapeutic radiopharmaceuticals, involving isotopes such as iodine-123, iodine-131, technetium-99m, and samarium-153. The new plant's production plan is based on the demand for radioisotope products from Russian medical institutions through 2030. The company...

2026-08-26

Molecular Partners Advances DLL3 Radiopharmaceutical MP0712 to Higher Dose Cohort

Swiss clinical-stage biotechnology company Molecular Partners AG recently announced its business progress and financial results for the first half of 2026. The company stated that its DLL3-targeting radioactive DARPin therapy MP0712 has advanced to the second therapeutic dose level in a U.S. multicenter Phase 1/2a clinical study, and patient enrollment for the new dose cohort is currently underway. MP0712 is a radiopharmaceutical targeting the tumor-associated antigen DLL3, carrying a therapeutic alpha-emitting radionuclide lead-212 (Pb-212) payload, co-developed by Molecular Partners and Orano Med, primarily for small cell lung cancer and other neuroendocrine tumors. According to the company's disclosure, the first dose cohort of MP0712...

2026-08-26

Russia and Algeria Advance Cooperation in Peaceful Uses of Nuclear Energy

August 22 news, Russian Ambassador to Algeria Alexey Solomatin said in an interview that Russia and Algeria are advancing cooperation in the field of peaceful uses of nuclear energy, with direct working contacts established between the relevant agencies of the two countries. Solomatin stated that cooperation between the two countries in this field is expanding. The basis for bilateral cooperation is the Intergovernmental Agreement on Cooperation in the Peaceful Uses of Nuclear Energy signed in 2014. In addition, Russia and Algeria signed the Roadmap for Cooperation in the Peaceful Uses of Nuclear Energy during the 2024 International Atomic Energy Expo (Atomexpo), outlining the main directions of bilateral cooperation. He noted that the practical implementation of the agreements will begin in 2...

2026-08-25

Atom High-Tech Adds New Radiopharmaceutical Production Base in Changchun

The Jilin Provincial Medical Products Administration issued a public notice on August 21 stating that, in accordance with the Drug Administration Law of the People's Republic of China, the Regulations on the Administration of Radiopharmaceuticals, the Measures for the Supervision and Administration of Drug Production, and other relevant provisions, following on-site inspection and review approval, it intends to issue the Radiopharmaceutical Production License to Changchun Atom High-Tech Pharmaceutical Co., Ltd. The public notice period is 5 working days, subject to public supervision. The notice information shows that the registered address of Changchun Atom High-Tech Pharmaceutical Co., Ltd. is located at No. 770 Shengye Road, Beihu Science and Technology Development Zone, Changchun City, Jilin Province, and the proposed production address for the license is consistent with the registered address. The proposed production scope for this license is small-volume injections for in vivo radiopharmaceuticals, involving products such as Sodium Pertechnetate [99mTc] Injection, Technetium [99mTc] Methylenediphosphonate Injection, Technetium [99mTc] Methoxyisonitrile Injection, Technetium [99mTc] Pentetate Injection, Technetium [99mTc] Ethyl Cysteinate Dimer Injection, and Technetium [99mTc] Etifenin Injection.

2026-08-24